Organoids are in vitro miniaturized and simplified model systems of organs that have gained
enormous interest for modelling tissue development and disease, and for personalized …

Combination therapies are superior to monotherapy for many cancers. This advantage was
historically ascribed to the ability of combinations to address tumor heterogeneity, but …

Triple-negative breast cancer (TNBC) is a collection of biologically diverse cancers
characterized by distinct transcriptional patterns, biology, and immune composition. TNBCs …

Triple-negative breast cancer (TNBC) remains the most challenging breast cancer subtype
to treat. To date, therapies directed to specific molecular targets have rarely achieved …

Abstract Models that recapitulate the complexity of human tumors are urgently needed to
develop more effective cancer therapies. We report a bank of human patient-derived …

Breast cancer (BC) comprises multiple distinct subtypes that differ genetically,
pathologically, and clinically. Here, we describe a robust protocol for long-term culturing of …

Patient-derived xenografts (PDXs) and patient-derived organoids (PDOs) have been shown
to model clinical response to cancer therapy. However, it remains challenging to use these …

Patient-derived xenografts (PDXs) have become a prominent cancer model system, as they
are presumed to faithfully represent the genomic features of primary tumors. Here we …

Poly-(ADP)-ribose polymerase (PARP) inhibition is synthetic lethal with deficiency for
homologous recombination (HR), a pathway essential for DNA double-strand break repair …

A synthetic lethal interaction occurs between two genes when the perturbation of either gene
alone is viable but the perturbation of both genes simultaneously results in the loss of …